[Characterisation of DNA methylation biomarkers for bladder cancer].
Despite considerable advances in recent years in our understanding of the genetic changes occurring in urinary bladder cancer, similar progress in the field of epigenetics has hitherto been lacking. Increasingly, however, focus has shifted in the direction of aberrant DNA methylation as a result of recent studies showing the direct impact of such promoter hypermethylation on the loss of tumor suppressor gene expression and function, therefore potentially affecting tumor genesis and progression. The purpose of this study is the identification and characterization of new DNA methylation markers in urinary bladder cancer, with the expectation that these markers could then be incorporated in a multi-gene panel for clinical use in early cancer detection. In addition, better understanding of the signalling pathways involved will undoubtedly impact the development of new treatment strategies. Potential candidate genes, including the Wnt antagonist SFRP5 among others, will be validated by different epigenetic techniques using invasive and superficial urothelial cell lines as well as tumor and urine samples from bladder cancer patients.
Antony
P
P
Institut für Pathologie, Arbeitsgruppe Molekulare Onkologie, Universitätsklinikum der RWTH Aachen, Aachen.
Rose
M
M
Gaisa
N T
NT
Alkaya
S
S
Heidenreich
A
A
Knüchel
R
R
Dahl
E
E
D048868:Adaptor Proteins, Signal Transducing; D014408:Biomarkers, Tumor / Q000235:genetics*; D002295:Carcinoma, Transitional Cell / Q000175:diagnosis / Q000235:genetics* / Q000473:pathology*; D045744:Cell Line, Tumor; D002872:Chromosome Deletion; D019175:DNA Methylation / Q000235:genetics*; D004252:DNA Mutational Analysis; D042241:Early Diagnosis; D057890:Epigenomics; D005136:Eye Proteins / Q000235:genetics; D006801:Humans; D008565:Membrane Proteins / Q000235:genetics; D009361:Neoplasm Invasiveness / Q000235:genetics / Q000473:pathology; D009367:Neoplasm Staging; D011379:Prognosis; D011401:Promoter Regions, Genetic / Q000235:genetics; D012333:RNA, Messenger / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D001743:Urinary Bladder / Q000473:pathology; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000473:pathology*; D000094742:Secreted Frizzled-Related Proteins
D048868:Adaptor Proteins, Signal Transducing; D014408:Biomarkers, Tumor; D005136:Eye Proteins; D008565:Membrane Proteins; D012333:RNA, Messenger; C118511:SFRP5 protein, human; D000094742:Secreted Frizzled-Related Proteins
Nat Rev Genet. 2002 Jun;3(6):415-28
12042769
Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2109-16
16609023
Cancer Res. 2001 Sep 15;61(18):6688-92
11559536
Br J Cancer. 2008 Mar 25;98(6):1147-56
18283316
Int J Cancer. 2003 May 1;104(5):611-6
12594816
N Engl J Med. 2008 Mar 13;358(11):1148-59
18337604
J Natl Cancer Inst. 2006 Jul 19;98(14):996-1004
16849682
Carcinogenesis. 2006 Mar;27(3):361-73
16352616
Proc Natl Acad Sci U S A. 1971 Apr;68(4):820-3
5279523
Eur Urol. 2008 May;53(5):909-16
18162285
Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1603-8
9990071
Clin Cancer Res. 2005 Jun 15;11(12):4415-29
15958626
Clin Cancer Res. 2004 Nov 15;10(22):7457-65
15569975
Nat Med. 1997 Jun;3(6):621-4
9176487
Cancer Res. 2001 Apr 15;61(8):3225-9
11309270
Histopathology. 2009 Jun;54(7):885-900
19178589
N Engl J Med. 2003 Nov 20;349(21):2042-54
14627790
Curr Opin Oncol. 2009 May;21(3):272-7
19370808
Clin Cancer Res. 2007 Apr 1;13(7):2046-53
17404085
Clin Cancer Res. 2004 Mar 15;10(6):1887-93
15041703
Nat Rev Genet. 2007 Apr;8(4):286-98
17339880
Int J Cancer. 2001 Oct 15;94(2):153-6
11668491
Carcinogenesis. 2008 May;29(5):991-8
18356147